ChromaDex Corporation provided earnings guidance for 2024. For the full year, the Company expects the trajectory of revenue growth to continue, projecting a higher rate of revenue growth than the prior year growth of 16%.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.575 USD | +3.92% | +22.71% | +153.15% |
Apr. 23 | Chromadex Announces Inaugural Major Grocery Debut of Tru Niagen® At Sprouts Farmers Market | CI |
Apr. 09 | Roth MKM Raises Price Target on ChromaDex to $6 From $4.25, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+153.15% | 260M | |
+2.44% | 42.75B | |
+47.70% | 41.61B | |
+11.86% | 41.34B | |
-8.83% | 26.59B | |
+7.00% | 25.49B | |
-22.60% | 18.12B | |
+30.44% | 12.24B | |
-1.93% | 11.76B | |
+9.20% | 11B |
- Stock Market
- Equities
- CDXC Stock
- News ChromaDex Corporation
- ChromaDex Corporation Provides Earnings Guidance for 2024